Sign in
Taking people in United StatesPhase 2

Tests sacituzumab govitecan in people with mesothelioma

Tests sacituzumab govitecan in adults with previously treated mesothelioma.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 7 sites
Trial code
Registry title
A Study of Sacituzumab Govitecan in People With Mesothelioma
Status
Recruiting
Phase
Phase 2
People taking part
33 people, planned
Started
21 Jun 2024
Expected to end
21 Jun 2029
Type of study
Interventional
Treatments tested
  • Sacituzumab govitecan-hziy
Record updated
28 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diffuse pleural mesothelioma who have already had at least one treatment. They will receive sacituzumab govitecan-hziy.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Diffuse pleural mesothelioma confirmed by tissue testing, with disease that can be measured on scans.
Earlier treatment
Must have had at least one earlier treatment by drug into the blood (platinum/pemetrexed, immunotherapy, or both). Cannot have had cytotoxic or immune treatment within 3 weeks before day 1.

Main reasons for not taking part

  • Allergy to irinotecan or to a part of sacituzumab govitecan-hziy
  • Another cancer that is getting worse or needs treatment
  • Positive hepatitis B surface antigen or positive hepatitis C antibody, with some exceptions
  • Heart attack, stroke or unstable angina within 6 months, or serious heart failure
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial
  • Patient age ≥ 18 at time of consent
  • Pathologically confirmed diffuse pleural mesothelioma
  • Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)
  • Measurable disease as defined primarily by the modified RECIST criteria for mesothelioma (at PI discretion RECIST v1.1 may be used)
  • Consent to undergo a biopsy prior to Cycle 1 Day 1 and Cycle 3 Day 1 if deemed medically safe and feasible
  • Eastern Cooperative Oncology Group (ECOG) score 0 or Karnofsky Performance Status ≥ 70%
  • Adequate organ function, defined as; Absolute neutrophil count ≥ 1.5K/mcL; Platelet count ≥ 100K/mcL; Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula); Hemoglobin > 9g/dL (prior transfusion permitted if not within 7 days of enrollment); Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases or <3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits; AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)
  • If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy

Who cannot take part

  • Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
  • Prior hypersensitivity to irinotecan or any components of sacituzumab govitecan-hziy
  • Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)
  • Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg); o NOTE: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Patients who fit these criteria must use Hep B prophylaxis during treatment. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing
  • Positive hepatitis C antibody (anti-HCV); o NOTE: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible
  • Pregnant women or women who are breastfeeding or of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment. If the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last treatment. Highly effective contraception includes either 2 barrier methods (diaphragm, condom by the partner, copper intrauterine device, sponge, or spermicide), or 1 barrier method and 1 hormonal method (any oral, subcutaneous, intrauterine, or intramuscular registered and marketed contraceptive agent that contains an estrogen and/or a progesterone agent)
  • Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial within the opinion of the investigator
  • Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, or in situ cervical cancer after definitive treatment
  • Myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug
  • Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1
  • Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:; Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment); CD4 count < 350 cells/mm3 at screening; AIDS-defining opportunistic infection within 6 months of start of screening; Not agreeing to start ART and be on ART > 4 weeks plus having HIV viral load <400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled)

Where in United States

  • Memorial Sloan Kettering Basking RidgeBasking Ridge, United StatesContact: Michael Offin, MDTaking people
  • Memorial Sloan Kettering Cancer Center - CommackCommack, United StatesContact: Michael Offin, MDTaking people
  • Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Michael Offin, MDTaking people
  • Memorial Sloan Kettering MonmouthMiddletown, United StatesContact: Michael Offin, MDTaking people
  • Memorial Sloan Kettering BergenMontvale, United StatesContact: Michael Offin, MDTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Michael Offin, MDTaking people
  • Memorial Sloan Kettering NassauUniondale, United StatesContact: Michael Offin, MDTaking people

About the trial

What the trial wants to find out

Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.

The group in the trial

  • Participants with MesotheliomaTreatment being tested

    Participants will have pathologically confirmed diffuse pleural mesothelioma. Patients will undergo cross-sectional imaging after the first 2 cycles and subsequently after every 3 cycles until disease progression. Biopsies will take place at screening, prior to cycle 3, and an optional biopsy at the end of treatment if consent was obtained and deemed to be safe and feasible. Patients treated on study who are removed prior to the Cycle 3 tumor assessment will be evaluated for toxicity only and replaced. All patients treated past the Cycle 3 tumor assessment will be include in the toxicity and efficacy assessments.

    Treatment: Sacituzumab govitecan-hziy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma
Plain-language title
Tests sacituzumab govitecan in people with mesotheliomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 May 2026